Updated ASCO Guideline for Managing Hereditary Breast Cancer
Posted: Friday, June 25, 2021
The American Society of Clinical Oncology (ASCO) released guidelines recommending adjuvant olaparib for 1 year in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations after completing neoadjuvant chemotherapy and local treatment such as radiation. The updated 2020 ASCO guideline is based on new data from the OlympiA trial presented during the 2021 ASCO Annual Meeting and published in The New England Journal of Medicine.
“The findings from the OlympiA trial mark a significant improvement in the care of these patients. ASCO’s Expert Guideline Panel and Evidence-based Medicine Committee noted this and then quickly produced and provisionally approved this guideline update to enable patients to begin to benefit from this research advance as quickly as possible,” Julie Gralow, MD, FACP, FASCO, ASCO Executive Vice President and Chief Medical Officer, said in an ASCO press release.
Results from the OlympiA trial showed significant improvement in invasive and distant disease–free survival when patients with early-stage, HER2-negative breast cancer with a high risk of recurrence and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants were administered the PARP inhibitor olaparib compared with a placebo.
Other updates include the following:
- Recommendation for adjuvant olaparib for patients with triple-negative breast cancer with tumor size greater than 2 cm or any involved axillary nodes who had surgery first
- Recommendation for adjuvant olaparib for patients with hormone receptor–positive disease who have had at least four involved axillary lymph nodes
- Recommendation for adjuvant olaparib in patients with triple-negative breast cancer and any residual cancer who had neoadjuvant chemotherapy
- Recommendation for adjuvant olaparib for patients with residual disease and an estrogen receptor status and tumor grade (CSP+EG) score ≥ 3.
For more information on the guideline updates, visit asco.org.
